Tapentadol for Multimodal Pain Management

Pasero, Chris

doi:10.1016/j.jopan.2011.06.001

Cited by 6 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tapentadol has not yet been evaluated for use in patients with severely compromised renal or hepatic function [ 18 ] and thus should not be used in this population. Patients with mild hepatic dysfunction may be administered tapentadol PR with no dosage adjustments, but those with moderate hepatic impairment should be started at the lowest possible dose strength and should not be administered tapentadol more than once over a 24-h period [ 90 ].…”

Section: Tapentadol Use In Special Populationsmentioning

confidence: 99%

“…It has no official place on World Health Organization (WHO) pain ladder [ 16 ] as it is a newer product that was not on the market when WHO published its guidelines for cancer pain patients. Tapentadol is a unique product in that its dual analgesic mechanisms of action are combined in one molecule [ 17 , 18 ]. In that way, it must be considered as an atypical opioid (Fig.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain

et al. 2018

View full text Add to dashboard Cite

Tapentadol is a novel pain reliever with apparently synergistic dual mechanisms of action, capable of addressing both nociceptive and neuropathic components of chronic pain. As an effective analgesic with good tolerability, tapentadol may be appropriate for patients suffering from severe chronic pain associated with low back pain (LBP) or osteoarthritis (OA). Efficacy studies of tapentadol in populations of patients with severe chronic LBP or OA pain suggest that tapentadol is non-inferior to oxycodone. Its tolerability, especially with respect to gastrointestinal (GI) side effects, may be better than that of other strong opioids in clinical trials and analyses of multiple trials. Patient satisfaction with tapentadol extended release for chronic noncancer pain syndromes is good. Although tapentadol has an opioid component with abuse liability, it appears to be a difficult opioid for tampering with less appeal to abusers than other opioids. For patients with severe LBP and OA pain, tapentadol appears to hold promise as a safe, effective therapeutic option.

show abstract

Section: Tapentadol Use In Special Populationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although tapentadol does not block serotonin reuptake, serotonin syndrome was reported as a serious adverse event. It is strongly advised to not simultaneously use medications with a serotonin-reuptake inhibition mechanism or monoamine oxidase inhibitors in combination with tapentadol, as it is believed that the increased norepinephrine levels (NRI component of tapentadol mechanism of action) can lead to increased serotonin levels with development of serotonin syndrome without specifying the mechanism [23].…”

Section: Drug Name (Generic) Tapentadol Phasementioning

confidence: 99%

“…Also, the authors of the study observed that after the intravenous administration of tapendadol sedation and salivation occurred to a mild degree [32]. Some of the adverse events such as shivering, nausea, sweating and confusion were felt to be due to the increased level of serotonin secondary elevated to NRI levels [23]. Another study in rabbits showed the benefits of tapentadol for providing post-operative analgesia [33].…”

Section: Veterinary Usementioning

confidence: 99%

Unique pharmacology of tapentadol for treating acute and chronic pain

Knežević

Tverdohleb

Knezevic

et al. 2015

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

“…Multiple reviews of tapentadol exist [13,[16][17][18][19][20][21][22][23][24][25][26]; however, none extensively review tapentadol ER for the specific indication of PDPN. The purpose of this review is to assess the efficacy and safety of tapentadol ER in adult populations with PDPN.…”

Section: Tapentadol Ermentioning

confidence: 99%

Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy

Desai

Freeman

Huang

et al. 2014

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Painful diabetic peripheral neuropathy is difficult to treat, partially because the underlying mechanism of pain is not fully understood. Various treatment guidelines recommend first-line agents, such as α2-δ ligands, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants but combination therapy of alternative agents including opiates is often warranted. Tapentadol extended-release has a novel dual mechanism of action; it is both a mu-opioid receptor agonist and a norephinephrine reuptake inhibitor. It has been in the spotlight since it was FDA-approved specifically for the treatment of painful diabetic peripheral neuropathy in 2012. Previous reviews of tapentadol have focused on chronic pain. The purpose of this review article is to assess the efficacy and safety of tapentadol extended-release in adult populations with painful diabetic peripheral neuropathy and provide guidance for formulary decisions.

show abstract

Tapentadol for Multimodal Pain Management

Cited by 6 publications

References 28 publications

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain

Unique pharmacology of tapentadol for treating acute and chronic pain

Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy

Contact Info

Product

Resources

About